{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:59:03Z","timestamp":1781089143519,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>epidermal growth factor receptor (EGFR) mutations play a pivotal role in non-small cell lung cancer (NSCLC), with the EGFR exon 20 insertion (EGFR20ins) mutation being the third most prevalent alteration in the EGFR gene. Patients harboring this mutation typically exhibit a greater tumor burden and poorer overall prognosis. This mutation is strongly associated with resistance to EGFR-TKIs, presenting significant challenges for clinical management. Furmonertinib, an innovative third-generation EGFR-TKI, has been validated in numerous trials for its effectiveness in targeting the EGFR20ins mutation. Against this background, the study aims to explore the clinical application of furmonertinib in patients with advanced EGFR20ins-mutant NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A patient with advanced EGFR20ins-mutant NSCLC initially presented with a significant tumor burden, resulting in rapid disease progression and a decline in quality of life, which subsequently led to a poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Next-generation sequencing of the tumor tissue identified an EGFR20ins mutation (p.p772_H773insPHP) with a mutation prevalence of 83.58%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received high-dose furmonertinib as first-line treatment. Throughout the treatment, tumor burden, disease stability, progression-free survival (PFS), and adverse effects were closely monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient experienced prolonged advantages from high-dose furmonertinib as initial therapy and attained a PFS of 27 months. The patient demonstrated substantial reduction in tumor burden, attained extended disease stability, and noted enhancements in overall quality of life, accompanied by tolerable adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Furmonertinib, as a third-generation EGFR-TKI, demonstrated substantial efficacy in patients with advanced EGFR20ins-mutant NSCLC, significantly extending PFS and improving quality of life. This drug offers a promising new treatment option for patients with resistance to conventional therapies. Further studies will help validate the application of furmonertinib in a broader patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046998","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:01:30Z","timestamp":1769191290000},"page":"e46998","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6960-9419","authenticated-orcid":false,"given":"Qilin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"},{"name":"School of Medical Imaging, North Sichuan Medical College, Nanchong, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyu","family":"You","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncai","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gui","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China"},{"name":"School of Medical Imaging, North Sichuan Medical College, Nanchong, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260610","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer.","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R4-20260610","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20insertion mutations in non-small-cell lung cancer:preclinical data and clinica l implications.","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2022.03.005","article-title":"Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.","volume":"168","author":"Minchom","year":"2022","journal-title":"Lung Cancer"},{"key":"R6-20260610","doi-asserted-by":"crossref","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial.","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"R7-20260610","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"key":"R8-20260610","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2022.04.020","article-title":"The impact of TP53 comutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.","volume":"170","author":"Christopoulos","year":"2022","journal-title":"Eur J Cancer"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC.","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s40265-021-01588-w","article-title":"Furmonertinib: first approval.","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"R11-20260610","first-page":"100614","article-title":"The impact of on-target resistance mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 insertion mutation active tyrosine kinase inhibitors.","volume":"5","author":"Kobayashi","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"R12-20260610","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41401-021-00667-8","article-title":"Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans.","volume":"43","author":"Meng","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC With EGFR T790M mutation.","volume":"15","author":"Shi","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R14-20260610","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study.","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R15-20260610","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jtho.2025.05.004","article-title":"Emerging role of targeted therapies combined with radiotherapy in inoperable stages I to III NSCLC: a review from the IASLC ART subcommittee.","volume":"20","author":"Jones","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R16-20260610","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","article-title":"Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).","volume":"65","author":"Chinnaiyan","year":"2005","journal-title":"Cancer Res"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/atm-22-1167","article-title":"Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report.","volume":"10","author":"Jia","year":"2022","journal-title":"Ann Transl Med"},{"key":"R19-20260610","doi-asserted-by":"crossref","first-page":"1053805","DOI":"10.3389\/fphar.2023.1053805","article-title":"Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: a case report.","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"R20-20260610","doi-asserted-by":"crossref","first-page":"964606","DOI":"10.3389\/fphar.2022.964606","article-title":"Case report: a good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: a case report and literature review.","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R21-20260610","doi-asserted-by":"crossref","first-page":"e36667","DOI":"10.1097\/MD.0000000000036667","article-title":"First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain \u03b1C-helix: two case reports and a literature review.","volume":"102","author":"Han","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R22-20260610","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1097\/MJT.0000000000001504","article-title":"Successful salvage therapy with a high dose of furmonertinib in a case of lung adenocarcinoma harboring EGFR Exon 20 insertion.","volume":"30","author":"Jiang","year":"2023","journal-title":"Am J Ther"},{"key":"R23-20260610","first-page":"241","article-title":"First-line treatment with furmonertinib mesylate in lung adenocarcinoma patient with EGFR Exon 20 insertion mutantion.","volume":"27","author":"Li","year":"2024","journal-title":"Chin J Lung Cancer"},{"key":"R24-20260610","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer.","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2019.12.013","article-title":"Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.","volume":"141","author":"Veggel","year":"2020","journal-title":"Lung Cancer"},{"key":"R26-20260610","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S2213-2600(23)00379-X","article-title":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.","volume":"12","author":"Wang","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R27-20260610","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions.","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:01:56Z","timestamp":1781085716000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046998","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}